M
Magnet Biomedicine
Magnet Biomedicine is revolutionizing human medicine with molecular glues
About Magnet Biomedicine
Magnet Biomedicine, founded in 2019, is a biotechnology company focused on advancing the discovery and development of a class of small molecules known as molecular glues. The company officially launched in September 2023 with a $50 million Series A financing round co-led by Newpath Partners and ARCH Venture Partners. The company was established by a distinguished group of scientists, including molecular glue researcher Stuart Schreiber, 2017 Nobel Laureate Michael Rosbash, chemoproteomics pioneer Benjamin Cravatt, human geneticist Richa Saxena, and chemical biologist David Spiegel. This team's collective expertise in chemistry, biology, and genetics forms the scientific backbone of the company.
The company operates in the biopharmaceutical market, specifically focusing on therapeutics that can address historically undruggable protein targets. Its business model centers on the discovery and development of these novel medicines, with a strategy that includes forming partnerships with larger pharmaceutical companies. In a significant milestone, Magnet entered into a collaboration and license agreement with Eli Lilly to discover, develop, and commercialize molecular glue therapeutics for oncology. This deal included substantial upfront and near-term payments, with the potential for over a billion dollars in milestone payments plus royalties.
Magnet Biomedicine's core technology is its proprietary TrueGlue™ discovery platform. This platform utilizes advanced screening technologies, proprietary chemical libraries, and human-biology-driven target selection to rationally design 'TrueGlues'. Unlike many existing approaches that focus on protein degradation, Magnet's technology aims to induce novel protein-protein interactions. These engineered small molecules bring together a disease-relevant target protein and a 'presenter' protein, which can lead to various therapeutic outcomes beyond just degradation, such as inhibiting protein function in a tissue-specific manner or stabilizing proteins. This approach offers the potential to create highly selective drugs that minimize off-target toxicities. The company is initially targeting diseases with strong genetic and clinical validation in areas such as oncology, cardiovascular disease, and immune disorders.
Source: Dealroom company dataNews
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Sep 2023 | $50M | $200M | ARCH Venture Partners · Newpath Partners | ↗ |
Growth signals
Latest recorded traffic for Magnet Biomedicine is 1.8K monthly website visits, up 20% over the last three months. Magnet Biomedicine's team grew 600% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Magnet Biomedicine in the Boston ecosystem
The Magnet Biomedicine office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
ARCH Venture Partners
Newpath Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Magnet Biomedicine on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Magnet Biomedicine’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








